KMDS
E-submission
Articles
- Page Path
- HOME > J Mov Disord > Volume 11(3); 2018 > Article
-
Original Article
Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson’s Disease -
Young Eun Kim1, Han-Joon Kim2, Ji Young Yun3, Woong-Woo Lee4, Hui-Jun Yang5, Jong-Min Kim6, Beomseok Jeon2
-
Journal of Movement Disorders 2018;11(3):133-138.
DOI: https://doi.org/10.14802/jmd.18022
Published online: September 30, 2018
1Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea
2Department of Neurology and Movement Disorders Center, Parkinson Study Group, Seoul National University Hospital, Seoul, Korea
3Department of Neurology, Ewha Womans University Mokdong Hospital, Seoul, Korea
4Department of Neurology, Eulji General Hospital, Seoul, Korea
5Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
6Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Sungnam, Korea
- Corresponding author: Beomseok Jeon, MD, PhD, https://orcid.org/0000-0003-2491-3544 Department of Neurology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea / Tel: +82-2-2072-2876 / Fax: +82-2- 3672-7553 / E-mail: brain@snu.ac.kr
• Received: April 19, 2018 • Revised: July 7, 2018 • Accepted: July 23, 2018
Copyright © 2018 The Korean Movement Disorder Society
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ABSTRACT
-
Objective Musculoskeletal problems are more common in patients with Parkinson’s disease (PD) than in normal elderly, but the impact of musculoskeletal problems on health-related quality of life (HRQoL) in patients with PD is unknown.
-
Methods Four hundred consecutive patients with PD were enrolled for the evaluation of musculoskeletal problems and HRQoL. HRQoL was assessed by the 36-Item Short Form Health Survey, which comprised physical health and mental health.
-
Results Of the total patients, 265 patients had musculoskeletal problems, and 135 patients did not have musculoskeletal problems. Patients with musculoskeletal problems reported lower levels of HRQoL in terms of physical health than did patients without musculoskeletal problems (p < 0.05). In women, all components of physical health were lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p < 0.05). Meanwhile, in men, only the bodily pain score of physical health was lower in patients with musculoskeletal problems than in patients without musculoskeletal problems. Mental health and physical health were negatively correlated with depression, Unified Parkinson’s Disease Rating Scale I & II scores, and pain severity from musculoskeletal problems, in that order (p < 0.01 for all).
-
Conclusion These results suggest that musculoskeletal problems in patients with PD affect HRQoL significantly, mainly in terms of physical health rather than mental health and especially in women rather than men. Musculoskeletal problems should not be overlooked in the care of patients with PD.
Musculoskeletal problems are very common (45–66.3%) in patients with Parkinson’s disease (PD) [1,2]. However, there is limited evidence for the impact of musculoskeletal problems on quality of life (QoL) in patients with PD [3]. One paper evaluating 48 PD patients reported that bradykinesia and musculoskeletal impairments are correlated with life satisfaction [4]. Andreadou et al2 reported that even though musculoskeletal problems are the most common comorbidity in patients with PD, depression is more of a contributing factor to QoL than are musculoskeletal problems in patients with PD [2]. In our previous paper evaluating musculoskeletal problems in patients with PD, 31.8% (83/263) of PD patients with musculoskeletal problems responded that musculoskeletal problems limited their activity of daily living more than did the PD symptoms [1].
Musculoskeletal problems are known to be the most common cause of physical disability in the general population [5]. In addition, musculoskeletal disorders have been associated with the largest losses of QoL in the general population [6]. Because PD usually develops in old age and has a long disease duration, musculoskeletal problems in patients with PD could be an important issue that cannot be ignored [7].
In this study, we estimated the impact of musculoskeletal problems on health-related QoL (HRQoL) in patients with PD, focusing on the following questions.
1) Do musculoskeletal problems affect HRQoL in PD patients? Which components among HRQoL are mainly affected?
2) What types of clinical characteristics affect musculoskeletal problems in PD patients?
- Subjects
- Clinical assessments
- Statistical assessments
MATERIALS & METHODS
This study was designed as a cross-sectional evaluation of musculoskeletal problems in 400 patients with PD. All subjects were from the PD cohort of the Movement Disorder Clinic of Seoul National University Hospital: 265 patients with musculoskeletal problems and 135 patients without musculoskeletal problems. Details of the case-finding procedures and other characteristics of the musculoskeletal problems have been published elsewhere [1]. Briefly, patients were enrolled consecutively in an outpatient clinic from October 2011 to June 2012, and their musculoskeletal problems were evaluated. Patients with atypical parkinsonism were excluded. Patients with severe cognitive or speech problems who could not explain their symptoms were excluded. This study was approved by the Institutional Review of Board at Seoul National University Hospital. Written informed consent was obtained from all participants.
Physicians interviewed all patients using a structured format. During the interview for the musculoskeletal problems, the following relevant evaluations, including the 36-Item Short Form Health Survey (SF-36), were performed at the same time.
1) Musculoskeletal problems are linked anatomically by their association with pain or impaired physical function [8]. The existence of current musculoskeletal problems was discriminated according to the criteria we described in our previous study [1]. In addition, pain intensity (using a visual analog scale, VAS) related to musculoskeletal problems was evaluated.
2) Demographic factors included sex, age, age at onset, PD duration, the Unified Parkinson’s Disease Rating Scale (UPDRS) scores, the Hoehn and Yahr (HY) stage, and the levodopa equivalent daily dose [9].
3) The Beck Depression Inventory (BDI), a selfreported questionnaire, was used to measure the severity of depression.
4) HRQoL was assessed with the SF-36 questionnaire, which is a validated questionnaire comprising 36 questions. SF-36 is mainly divided into 2 categories of physical health and mental health. Physical health and mental health are composed of 4 dimensions each; physical health includes physical functioning, role-physical, bodily pain and general health, and mental health comprises vitality, social functioning, role-emotion, and mental health (range 0–100, higher scores indicate a better health status) [10].
In the case of continuous variables, the differences in HRQoL or other demographic features according to the existence of musculoskeletal problems were evaluated by independent t-tests. Noncontinuous variables were compared by chi-squared tests. To analyze the true effect of the MS problem on HRQoL (SF-36), other covariates that are not of primary interest were adjusted for by analysis of covariance. In addition, the relationships between the pain severity from musculoskeletal problems and HRQoL, BDI, and other clinical factors were calculated with Pearson’s correlation coefficients. A p value of < 0.05 was considered significant in all tests. These statistical analyses were performed with IBM SPSS statistics software ver. 19.0 (IBM Corp., Armonk, NY, USA).
RESULTS
The clinical profiles of the PD cohort are summarized in Table 1, and all data except for the BDI scores were already published in our previous paper [1]. Women, older age, older onset of PD, a higher UPDRS part I and II summed score, and a higher BDI score were associated with the existence of musculoskeletal problems in PD (Table 1). To evaluate HRQoL between the groups with and without musculoskeletal problems, the SF-36 score was adjusted by these significant contributing factors. Patients with musculoskeletal problems reported lower levels of QoL in terms of physical functioning, bodily pain, and general health (p = 0.003, p < 0.001, and p = 0.013, respectively) than did patients without musculoskeletal problems. Physical health, which is the mean score of physical functioning, role-physical, bodily pain, and general health, was also lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p = 0.003). However, mental health scores were not different between the groups (Table 1).
In women, the BDI score was the only factor that was different between patients with and without musculoskeletal problems (p = 0.022). After adjusting for the BDI score, all the components of physical health were lower in patients with musculoskeletal problems than in patients without musculoskeletal problems (p < 0.05 for all). Mental health was not different between the groups (Table 2). In men, older age, older age at onset, and higher UPDRS I & II scores were significantly associated with musculoskeletal problems (p = 0.001, p = 0.001, and p < 0.001, respectively). All subscores of the SF-36 except for bodily pain were not different between the groups after adjusting for age, age at onset, and UPDRS I & II scores (Table 3).
In the correlation analysis between HRQoL and associated factors, mental health and physical health were more negatively correlated with the BDI score, UPDRS I & II scores, and pain severity from musculoskeletal problems, in that order (p < 0.01) (Table 4).
DISCUSSION
The present study has three main findings. First, musculoskeletal problems in PD affect HRQoL significantly, mainly in terms of physical health. Second, musculoskeletal problems in PD have different effects on QoL according to gender. Third, musculoskeletal problems as well as depression and UPDRS I & II are important factors associated with HRQoL in PD.
The existence of musculoskeletal problems in PD contributed to a poor QoL in terms of physical health. Regarding mental health, the existence of musculoskeletal problems did not have an impact on QoL. Although the UPDRS motor score and HY stage were not different based on the existence of musculoskeletal problems, HRQoL was poor regarding musculoskeletal problems even after adjusting for other factors, including UPDRS part I and II scores and age. In the general population, musculoskeletal problems are associated with the largest losses of QoL [6]. However, in PD, our study suggested that musculoskeletal problems were associated with a poor QoL in terms of physical health, although this association was weaker than the associations of PD symptoms or depression with a poor QoL.
Musculoskeletal problems are more common in women than in men and have more significant contributions to QoL in women than in men in terms of physical health. All components of physical health in women and bodily pain in men affected QoL by musculoskeletal problems in PD. Women are at a higher risk than men for musculoskeletal problems in the general population [8]. In addition, women reported neck and low back pain more frequently than men at the onset of PD [11]. However, it is difficult to know whether this is because of the difference in pain severity in men and women. In this study, the pain severity from musculoskeletal problems was not different between men and women (pain severity assessed by VAS score; median values were 1 and 2, and the means with SD were 1.79 ± 2.20 and 2.01 ± 2.23 in women and men, respectively, p = 0.347). Women with PD could be more susceptible to musculoskeletal problems than men with PD, which would have a greater impact on QoL.
Patients with musculoskeletal problems had higher depression scores than patients without musculoskeletal problems, and this was more prominent in the female population. In addition, depression was well correlated with pain severity from musculoskeletal problems. Musculoskeletal problems in PD may contribute, even partially, to depression. Another aspect was that depression was negatively correlated with QoL in both physical health and mental health categories. It was already reported that depression is the most consistent determinant affecting QoL in PD [2,12]. In this study, a higher depression score was strongly correlated with a lower QoL score. Depression, compared to other factors, was a more important factor contributing to HRQoL in patients with PD.
The strength of the present study is its relatively large PD sample. In addition, this is the first assessment of the impact of musculoskeletal problems on the QoL in patients with PD. This study has some limitations. First, musculoskeletal problems were assessed by physical examination and interview. Structured assessment tools such as imaging were not used, and experts in the field of musculoskeletal problems were not involved in the study. Second, this was a cross-sectional evaluation and did not include any longitudinal clinical outcomes.
In conclusion, musculoskeletal problems in PD affect HRQoL significantly, mainly in terms of physical health rather than mental health and especially in women rather than in men. Musculoskeletal problems should not be overlooked in the care of patients with PD.
Acknowledgments
This study was supported by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A101273).
Table 1.
Comparison of quality of life, sleep adjusted by sex, age, age at onset, UPDRS scores, and depression scores in all patients
| PD with MS (n = 265) | PD without MS (n = 135) | p-value*(†) | |
|---|---|---|---|
| Sex, Female, n (%) | 164 (61.9) | 53 (39.6) | < 0.001 |
| Diabetes, n (%) | 19 (7.2) | 15 (11.1) | 0.181 |
| Age (y) | 66.16 ± 8.34 | 63.11 ± 8.90 | -0.001 |
| Age at onset (y) | 58.91 ± 9.58 | 55.81 ± 10.51 | -0.003 |
| PD duration (y) | 7.52 ± 5.87 | 7.26 ± 4.82 | -0.654 |
| HY | 2.39 ± 1.85 | 2.17 ±.0.70 | -0.183 |
| UPDRS I & II | 11.11 ± 8.83 | 7.51 ± 6.88 | (< 0.001) |
| UPDRS III | 15.65 ± 8.48 | 15.03 ± 8.67 | -0.495 |
| LEDD (mg) | 767.95 ± 442.637 | 768.83 ± 452.698 | -0.985 |
| BDI | 16.68 ± 10.72 | 12.93 ± 9.45 | -0.001 |
| SF-36 | |||
| Physical functioning | 54.15 ± 22.93 | 68.26 ± 22.10 | 0.003 |
| Role-physical | 46.43 ± 41.72 | 56.98 ± 38.40 | 0.649 |
| Bodily pain | 63.93 ± 23.34 | 78.24 ± 22.60 | < 0.001 |
| General health | 46.66 ± 22.62 | 57.65 ± 22.13 | 0.013 |
| Physical health (total) | 52.79 ± 22.27 | 65.28 ± 22.13 | 0.003 |
| Vitality | 48.67 ± 22.27 | 57.71 ± 21.31 | 0.216 |
| Social functioning | 67.46 ± 26.16 | 72.02 ± 23.15 | 0.782 |
| Role-emotional | 46.56 ± 43.34 | 53.75 ± 43.96 | 0.708 |
| Mental healthy | 62.60 ± 19.63 | 67.08 ± 17.01 | 0.973 |
| Mental health (total) | 56.32 ± 23.16 | 62.64 ± 21.64 | 0.872 |
| SF-36 total score | 54.56 ± 21.87 | 63.96 ± 20.51 | 0.086 |
p-values for SF-36 scores were calculated by analysis of covariance, adjusted by sex, age, UPDRS I & II, and BDI.
* chi-squared test,
† Independent-sample t-test.
PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 2.
Comparison of quality of life adjusted by BDI score based on the existence of musculoskeletal problems in women
| PD with MS (n = 164) | PD without MS (n = 53) | p-value*(†) | |
|---|---|---|---|
| Age (y) | 65.28 ± 8.05 | 63.42 ± 7.93 | 0.142 |
| Age at onset (y) | 58.18 ± 9.32 | 57.47 ± 9.58 | 0.632 |
| PD duration (y) | 7.54 ± 6.52 | 5.98 ± 4.73 | 0.061 |
| HY | 2.29 ± 0.76 | 2.13 ± 0.78 | 0.187 |
| UPDRS I & II | 10.68 ± 8.02 | 8.47 ± 6.89 | 0.073 |
| UPDRS III | 15.66 ± 8.64 | 13.88 ± 8.29 | 0.189 |
| LEDD (mg) | 741.28 ± 405.09 | 684.82 ± 405.72 | 0.379 |
| BDI | 17.91 ± 11.33 | 13.89 ± 10.22 | 0.022 |
| SF-36 | |||
| Physical functioning | 50.76 ± 23.69 | 63.92 ± 22.77 | (0.005) |
| Role-physical | 43.04 ± 41.65 | 57.50 ± 35.45 | (0.029) |
| Bodily pain | 60.76 ± 23.61 | 74.95 ± 23.19 | (0.001) |
| General health | 43.64 ± 23.44 | 54.88 ± 23.53 | (0.025) |
| Physical health (total) | 49.50 ± 22.20 | 62.83 ± 20.03 | (0.002) |
| Vitality | 45.98 ± 22.79 | 53.79 ± 21.38 | (0.270) |
| Social functioning | 64.84 ± 26.92 | 76.08 ± 22.37 | (0.073) |
| Role-emotional | 44.51 ± 42.83 | 47.33 ± 41.56 | (0.689) |
| Mental healthy | 60.56 ± 19.87 | 67.59 ± 16.38 | (0.192) |
| Mental health (total) | 53.97 ± 23.01 | 61.32 ± 20.26 | (0.371) |
* t-test,
† analysis of covariance,
SF-36 was adjusted by BDI. PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 3.
Comparison of quality of life adjusted by age, age at onset, and UPDRS scores based on the existence of musculoskeletal problem in men
| PD with MS (n = 101) | PD without MS (n = 82) | p-value*(†) | |
|---|---|---|---|
| Age | 67.59 ± 8.66 | 62.91 ± 9.51 | 0.001 |
| Age at onset | 60.09 ± 9.92 | 54.74 ± 10.98 | 0.001 |
| PD duration | 7.50 ± 4.66 | 8.09 ± 4.72 | 0.398 |
| HY | 2.56 ± 2.84 | 2.20 ± 0.65 | 0.264 |
| UPDRS I & II | 11.82 ± 10.05 | 6.89 ± 6.85 | < 0.001 |
| UPDRS III | 15.63 ± 8.25 | 15.78 ± 8.88 | 0.905 |
| LEDD (mg) | 811.27 ± 496.69 | 823.13 ± 475.13 | 0.870 |
| BDI | 14.67 ± 9.35 | 12.30 ± 8.92 | 0.085 |
| SF-36 | |||
| Physical functioning | 59.38 ± 20.78 | 70.25 ± 22.51 | (0.068) |
| Role-physical | 50.52 ± 41.77 | 56.65 ± 40.37 | (0.456) |
| Bodily pain | 68.76 ± 22.32 | 80.31 ± 22.11 | (0.028) |
| General health | 51.53 ± 20.33 | 58.83 ± 21.49 | (0.097) |
| Physical health (total) | 57.48 ± 21.63 | 66.45 ± 21.94 | (0.263) |
| Vitality | 52.73 ± 20.69 | 59.90 ± 21.02 | (0.410) |
| Social functioning | 70.88 ± 24.73 | 70.00 ± 23.47 | (0.219) |
| Role-emotional | 48.80 ± 44.11 | 57.08 ± 45.38 | (0.815) |
| Mental healthy | 65.69 ± 18.73 | 66.73 ± 17.29 | (0.243) |
| Mental health (total) | 59.52 ± 23.10 | 63.43 ± 22.39 | (0.605) |
Abbreviations are the same as in Table 1.
* t-test,
† adjusted by age, age at onset, and UPDRS scores.
PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 4.
Pearson’s correlation coefficients between various factors
| Pain severity | Age | Age at onset of PD | UPDRS (I & II) | BDI | |
|---|---|---|---|---|---|
| Age | 0.026 | ||||
| Age at onset of PD | 0.023 | 0.868† | |||
| UPDRS (I & II) | 0.198† | 0.154† | 0.040 | ||
| BDI | 0.210† | 0.014 | -0.088 | 0.599† | |
| SF-36, physical health | -0.288† | -0.122* | 0.018 | -0.546† | -0.626† |
| SF-36, mental health | -0.217† | -0.020 | 0.098 | -0.521† | -0.690† |
- 1. Kim YE, Lee WW, Yun JY, Yang HJ, Kim HJ, Jeon BS. Musculoskeletal problems in Parkinson’s disease: neglected issues. Parkinsonism Relat Disord 2013;19:666–669.ArticlePubMed
- 2. Andreadou E, Anagnostouli M, Vasdekis V, Kararizou E, Rentzos M, Kontaxis T, et al. The impact of comorbidity and other clinical and sociodemographic factors on healthrelated quality of life in Greek patients with Parkinson’s disease. Aging Ment Health 2011;15:913–921.ArticlePubMed
- 3. Kim YE, Jeon BS. Musculoskeletal problems in Parkinson’s disease. J Neural Transm (Vienna) 2013;120:537–542.ArticlePubMedPDF
- 4. Dural A, Atay MB, Akbostanci C, Kucukdeveci A. Impairment, disability, and life satisfaction in Parkinson’s disease. Disabil Rehabil 2003;25:318–323.ArticlePubMed
- 5. Woolf AD. How to assess musculoskeletal conditions. History and physical examination. Best Pract Res Clin Rheumatol 2003;17:381–402.ArticlePubMed
- 6. Saarni SI, Härkänen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res 2006;15:1403–1414.ArticlePubMedPDF
- 7. Fahn S, Jankovic J, Hallett M. Principles and Practice of Movement Disorders. 2nd ed. Elsevier Saunders; 2011.
- 8. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ 2003;81:646–656.PubMedPMC
- 9. Grosset KA, Grosset DG. Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson’s disease. Clin Ther 2006;28:1063–1064.author reply 1064. ArticlePubMed
- 10. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–263.ArticlePubMed
- 11. Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM. Gender differences in Parkinson’s disease symptom profile. Acta Neurol Scand 2000;102:37–43.ArticlePubMed
- 12. Schrag A. Quality of life and depression in Parkinson’s disease. J Neurol Sci 2006;248:151–157.ArticlePubMed
REFERENCES
Figure & Data
References
Citations
Citations to this article as recorded by 
- Assessments scales for the evaluation of health-related quality of life in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy: a systematic review
Maria Lucia Maiuolo, Roberto Giorgini, Maria Grazia Vaccaro, Alessio Facchin, Andrea Quattrone, Aldo Quattrone
Frontiers in Psychology.2024;[Epub] CrossRef - Total knee arthroplasty in patients with Parkinson’s disease: A systematic review and meta-analysis protocol
Guangchen Sun, Hui Yu, Jun Cui, Ming Li, Yuefang Ru
Medicine.2022; 101(52): e32315. CrossRef - Quality of life of older adults in two contrasting neighbourhoods in Accra, Ghana
Dominic A. Alaazi, Devidas Menon, Tania Stafinski, Stephen Hodgins, Gian Jhangri
Social Science & Medicine.2021; 270: 113659. CrossRef - The Efficiency of Spa Rehabilitation in Chronic Ischemic Stroke Patients—Preliminary Reports
Bogumiła Pniak, Justyna Leszczak, Jadwiga Kurczab, Aleksandra Krzemińska, Joanna Pięta, Agnieszka Plis, Ewelina Czenczek-Lewandowska, Agnieszka Guzik
Brain Sciences.2021; 11(4): 501. CrossRef - Sex-specific effects of subthalamic nucleus stimulation on pain in Parkinson’s disease
Olga Khazen, Marisa DiMarzio, Kelsey Platanitis, Heather C. Grimaudo, Maria Hancu, Miriam M. Shao, Michael D. Staudt, Lucy Maguire, Vishad V. Sukul, Jennifer Durphy, Era K. Hanspal, Octavian Adam, Eric Molho, Julie G. Pilitsis
Journal of Neurosurgery.2021; 135(2): 629. CrossRef - An overview of pain in Parkinson's disease
Yi-Cheng Tai, Chin-Hsien Lin
Clinical Parkinsonism & Related Disorders.2020; 2: 1. CrossRef - Clinical Perspectives of Parkinson's Disease for Ophthalmologists, Otorhinolaryngologists, Cardiologists, Dentists, Gastroenterologists, Urologists, Physiatrists, and Psychiatrists
Ji-Hyun Choi, Jong-Min Kim, Hee Kyung Yang, Hyo-Jung Lee, Cheol Min Shin, Seong Jin Jeong, Won-Seok Kim, Ji Won Han, In-Young Yoon, Yoo Sung Song, Yun Jung Bae
Journal of Korean Medical Science.2020;[Epub] CrossRef - Parkinson's Disease Is Associated with Increased Complications, Readmission Rates, and Costs of Care after Total Hip Arthroplasty: A Matched-Cohort Analysis
Simon Katz, Kevin B. Marchand, Rushabh M. Vakharia, Hiba Anis, Nipun Sodhi, Nicolas S. Piuzzi, Michael A. Mont, Martin W. Roche
The Journal of Hip Surgery.2020; 4(03): 149. CrossRef - Chronic Pain Treatment Strategies in Parkinson’s Disease
Amber Edinoff, Niro Sathivadivel, Timothy McBride, Allyson Parker, Chikezie Okeagu, Alan D. Kaye, Adam M. Kaye, Jessica S. Kaye, Rachel J. Kaye, Meeta M. Sheth, Omar Viswanath, Ivan Urits
Neurology International.2020; 12(3): 61. CrossRef - Sex differences in the short-term and long-term effects of subthalamic nucleus stimulation in Parkinson's disease
Ryul Kim, Dallah Yoo, Ji-Hyun Choi, Jung Hwan Shin, Sangmin Park, Han-Joon Kim, Sun Ha Paek, Beomseok Jeon
Parkinsonism & Related Disorders.2019; 68: 73. CrossRef
Comments on this article
PubReader
ePub Link
Cite
XML Download- Related articles
-
- Accessibility of Device-Aided Therapies for Persons With Parkinson’s Disease in Poland
- A Survey of Perspectives on Telemedicine for Patients With Parkinson’s Disease
- Potential Link Between Cognition and Motor Reserve in Patients With Parkinson’s Disease
- Hand Movement-Induced Eyeblink Bursts in a Patient With Parkinson’s Disease
- Umami and Other Taste Perceptions in Patients With Parkinson’s Disease
Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson’s Disease
Musculoskeletal Problems Affect the Quality of Life of Patients with Parkinson’s Disease
| PD with MS (n = 265) | PD without MS (n = 135) | p-value |
|
|---|---|---|---|
| Sex, Female, n (%) | 164 (61.9) | 53 (39.6) | < 0.001 |
| Diabetes, n (%) | 19 (7.2) | 15 (11.1) | 0.181 |
| Age (y) | 66.16 ± 8.34 | 63.11 ± 8.90 | -0.001 |
| Age at onset (y) | 58.91 ± 9.58 | 55.81 ± 10.51 | -0.003 |
| PD duration (y) | 7.52 ± 5.87 | 7.26 ± 4.82 | -0.654 |
| HY | 2.39 ± 1.85 | 2.17 ±.0.70 | -0.183 |
| UPDRS I & II | 11.11 ± 8.83 | 7.51 ± 6.88 | (< 0.001) |
| UPDRS III | 15.65 ± 8.48 | 15.03 ± 8.67 | -0.495 |
| LEDD (mg) | 767.95 ± 442.637 | 768.83 ± 452.698 | -0.985 |
| BDI | 16.68 ± 10.72 | 12.93 ± 9.45 | -0.001 |
| SF-36 | |||
| Physical functioning | 54.15 ± 22.93 | 68.26 ± 22.10 | 0.003 |
| Role-physical | 46.43 ± 41.72 | 56.98 ± 38.40 | 0.649 |
| Bodily pain | 63.93 ± 23.34 | 78.24 ± 22.60 | < 0.001 |
| General health | 46.66 ± 22.62 | 57.65 ± 22.13 | 0.013 |
| Physical health (total) | 52.79 ± 22.27 | 65.28 ± 22.13 | 0.003 |
| Vitality | 48.67 ± 22.27 | 57.71 ± 21.31 | 0.216 |
| Social functioning | 67.46 ± 26.16 | 72.02 ± 23.15 | 0.782 |
| Role-emotional | 46.56 ± 43.34 | 53.75 ± 43.96 | 0.708 |
| Mental healthy | 62.60 ± 19.63 | 67.08 ± 17.01 | 0.973 |
| Mental health (total) | 56.32 ± 23.16 | 62.64 ± 21.64 | 0.872 |
| SF-36 total score | 54.56 ± 21.87 | 63.96 ± 20.51 | 0.086 |
| PD with MS (n = 164) | PD without MS (n = 53) | p-value |
|
|---|---|---|---|
| Age (y) | 65.28 ± 8.05 | 63.42 ± 7.93 | 0.142 |
| Age at onset (y) | 58.18 ± 9.32 | 57.47 ± 9.58 | 0.632 |
| PD duration (y) | 7.54 ± 6.52 | 5.98 ± 4.73 | 0.061 |
| HY | 2.29 ± 0.76 | 2.13 ± 0.78 | 0.187 |
| UPDRS I & II | 10.68 ± 8.02 | 8.47 ± 6.89 | 0.073 |
| UPDRS III | 15.66 ± 8.64 | 13.88 ± 8.29 | 0.189 |
| LEDD (mg) | 741.28 ± 405.09 | 684.82 ± 405.72 | 0.379 |
| BDI | 17.91 ± 11.33 | 13.89 ± 10.22 | 0.022 |
| SF-36 | |||
| Physical functioning | 50.76 ± 23.69 | 63.92 ± 22.77 | (0.005) |
| Role-physical | 43.04 ± 41.65 | 57.50 ± 35.45 | (0.029) |
| Bodily pain | 60.76 ± 23.61 | 74.95 ± 23.19 | (0.001) |
| General health | 43.64 ± 23.44 | 54.88 ± 23.53 | (0.025) |
| Physical health (total) | 49.50 ± 22.20 | 62.83 ± 20.03 | (0.002) |
| Vitality | 45.98 ± 22.79 | 53.79 ± 21.38 | (0.270) |
| Social functioning | 64.84 ± 26.92 | 76.08 ± 22.37 | (0.073) |
| Role-emotional | 44.51 ± 42.83 | 47.33 ± 41.56 | (0.689) |
| Mental healthy | 60.56 ± 19.87 | 67.59 ± 16.38 | (0.192) |
| Mental health (total) | 53.97 ± 23.01 | 61.32 ± 20.26 | (0.371) |
| PD with MS (n = 101) | PD without MS (n = 82) | p-value |
|
|---|---|---|---|
| Age | 67.59 ± 8.66 | 62.91 ± 9.51 | 0.001 |
| Age at onset | 60.09 ± 9.92 | 54.74 ± 10.98 | 0.001 |
| PD duration | 7.50 ± 4.66 | 8.09 ± 4.72 | 0.398 |
| HY | 2.56 ± 2.84 | 2.20 ± 0.65 | 0.264 |
| UPDRS I & II | 11.82 ± 10.05 | 6.89 ± 6.85 | < 0.001 |
| UPDRS III | 15.63 ± 8.25 | 15.78 ± 8.88 | 0.905 |
| LEDD (mg) | 811.27 ± 496.69 | 823.13 ± 475.13 | 0.870 |
| BDI | 14.67 ± 9.35 | 12.30 ± 8.92 | 0.085 |
| SF-36 | |||
| Physical functioning | 59.38 ± 20.78 | 70.25 ± 22.51 | (0.068) |
| Role-physical | 50.52 ± 41.77 | 56.65 ± 40.37 | (0.456) |
| Bodily pain | 68.76 ± 22.32 | 80.31 ± 22.11 | (0.028) |
| General health | 51.53 ± 20.33 | 58.83 ± 21.49 | (0.097) |
| Physical health (total) | 57.48 ± 21.63 | 66.45 ± 21.94 | (0.263) |
| Vitality | 52.73 ± 20.69 | 59.90 ± 21.02 | (0.410) |
| Social functioning | 70.88 ± 24.73 | 70.00 ± 23.47 | (0.219) |
| Role-emotional | 48.80 ± 44.11 | 57.08 ± 45.38 | (0.815) |
| Mental healthy | 65.69 ± 18.73 | 66.73 ± 17.29 | (0.243) |
| Mental health (total) | 59.52 ± 23.10 | 63.43 ± 22.39 | (0.605) |
| Pain severity | Age | Age at onset of PD | UPDRS (I & II) | BDI | |
|---|---|---|---|---|---|
| Age | 0.026 | ||||
| Age at onset of PD | 0.023 | 0.868 |
|||
| UPDRS (I & II) | 0.198 |
0.154 |
0.040 | ||
| BDI | 0.210 |
0.014 | -0.088 | 0.599 |
|
| SF-36, physical health | -0.288 |
-0.122 |
0.018 | -0.546 |
-0.626 |
| SF-36, mental health | -0.217 |
-0.020 | 0.098 | -0.521 |
-0.690 |
Table 1. Comparison of quality of life, sleep adjusted by sex, age, age at onset, UPDRS scores, and depression scores in all patients
chi-squared test, Independent-sample PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 2. Comparison of quality of life adjusted by BDI score based on the existence of musculoskeletal problems in women
analysis of covariance, SF-36 was adjusted by BDI. PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn
and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 3. Comparison of quality of life adjusted by age, age at onset, and UPDRS scores based on the existence of musculoskeletal problem in men
Abbreviations are the same as in Table 1. adjusted by age, age at onset, and UPDRS scores. PD: Parkinson’s disease, MS: musculoskeletal problems, HY: Hoehn and Yahr stage, UPDRS: the Unified Parkinson’s Disease Rating Scale, LEDD: levodopa equivalent daily dose, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
Table 4. Pearson’s correlation coefficients between various factors
PD: Parkinson’s disease, UPDRS: the Unified Parkinson’s Disease Rating Scale, BDI: Beck Depression Inventory, SF-36: 36-Item Short Form Health Survey.
